The company is conducting the second-stage study through a collaboration and license agreement with Kyowa Hakko Kirin. The company said these data were presented at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting on Monday.
Ultragenyx CEO and President Emil Kakkis said, "Patients with TIO have substantial hypophosphatemia, osteomalacia and fractures. These data support that KRN23 could potentially reverse some of these symptoms and improve bone health in patients."
The company disclosed that overall the study demonstrated improvement in serum phosphorus and other bone mineral metabolism measures that is in line with what was observed in trials of KRN23 in pediatric and adult patients with X-linked hypophosphatemia (XLH).
Following the news, the stock advanced $1.38, or 1.79 percent, to $78.50 in the pre-market trading on Monday. At time of publication, the stock was up 3.12 percent at $79.53.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
